fbpx

REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search
Covid-19

Antibody Levels Remain High Two Months After Receiving the Second Dose of the COVID-19 Vaccine

Antibody
Sheba study indicates only a minor, expected decline in antibody levels among recipients of the Pfizer-BioNTech vaccine

Two months after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine, 2,500 of Sheba Medical Center’s employees displayed high blood antibody levels according to a new Sheba study. While a minor decline in blood antibody levels was observed, Prof. Gili Regev-Yochay, Director of the Infectious Diseases Unit at Sheba, says that “this drop was expected, and should not cause alarm.”

Prof. Regev-Yochay added: “We observed blood antibody levels that were much higher than the required threshold in most of the study’s participants. The few participants that displayed a more significant drop are currently being examined to determine whether this drop is indicative of decreased protection against COVID-19 infection.

The initial study on the efficacy of the Pfizer-BioNTech vaccine also included the hospital staff and has shown that the initial results have shown high-level protection against the COVID-19. The study will continue, and participants will be tested again to determine blood antibody levels 3 months after receiving the second vaccine jab.

Related
Sheba and Mayo Clinic merge Data-Sharing Network
News May 18.
Sheba and Mayo Clinic Partner to Transform Patient Care Through an Innovative Data-Sharing Network
Sheba Medical Center has joined the Mayo Clinic Platform Connect, a global data-sharing network that aims to revolutionize healthcare. The groundbreaking platform provides a safe,…
Read More
Sheba Medical Center is working on enhancing patient safety with AI solutions.
News May 18.
Enhancing Patient Safety and Care with AI Solutions
With improving patient care a top priority, Sheba recognized technological innovation as an essential enabler of progress and transformation, with a particular emphasis on artificial…
Read More
IBD passport for patients with ulcerative colitis.
News May 17.
Meet the IBD Passport: A New Hope for Ulcerative Colitis and Crohn’s Disease Patients 
Ulcerative colitis (UC) and Crohn’s disease, the two most common forms of inflammatory bowel disease (IBD), can cause frustrating symptoms like diarrhea, abdominal pain, bloating,…
Read More